-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

How I Treat: Acute Myeloid Leukemia with Targetable Mutations (ticketed session for in-person participants)

Program: How I Treat
Sunday, December 8, 2024: 8:00 AM-9:00 AM
Aqua 314 (Hilton San Diego Bayfront)
Speaker:
Courtney D. DiNardo, MD, MSc, UT MD Anderson Cancer Center
Disclosures:
DiNardo: Amgen: Consultancy; Astellas: Consultancy, Honoraria; Notable Labs: Honoraria; AstraZeneca: Honoraria; Rigel: Research Funding; Loxo: Research Funding; Gilead: Consultancy; Riegel: Honoraria; Schrodinger: Consultancy, Honoraria; Servier: Consultancy, Honoraria, Other: meetingsupport, Research Funding; ImmuneOnc: Research Funding; Astex: Research Funding; Cleave: Research Funding; Foghorn: Research Funding; Immunogen: Honoraria; GSK: Consultancy, Honoraria; GenMab: Consultancy, Honoraria, Other: data safety board; Genetech: Honoraria; BMS: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria, Research Funding; Jazz: Consultancy, Honoraria; Stemline: Consultancy.
See more of: How I Treat
<< Previous Session | Next Session >>